Optimum Therapies Menomonie | |
1309 Stout Rd, Menomonie, WI 54751-2959 | |
(715) 233-6230 | |
Not Available |
Full Name | Optimum Therapies Menomonie |
---|---|
Type | Facility |
Speciality | Clinic/center - Physical Therapy |
Location | 1309 Stout Rd, Menomonie, Wisconsin |
Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1578287272 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
225100000X | Physical Therapist | (* (Not Available)) | Secondary |
261QP2000X | Clinic/center - Physical Therapy | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Optimum Therapies Menomonie 517 E Clairemont Ave, Eau Claire, WI 54701-6479 Ph: (715) 855-0408 | Optimum Therapies Menomonie 1309 Stout Rd, Menomonie, WI 54751-2959 Ph: (715) 233-6230 |
News Archive
More college students are finding health care on campus. The Wall Street Journal reports: "As more parents lose their jobs—and their insurance—in the recession, more college students are having to scramble for health care.
Migraine rates in a comprehensive Norwegian health study have climbed by 1% in a decade - that may not sound like much, but in the Norwegian context, it means 45,000 more migraine sufferers - and if the trend were to hold for the European Union, that would be an additional 5 million more people plagued by migraines. Researchers at the Norwegian University of Science and Technology (NTNU) are baffled by the cause of this trend.
Hospira, the world's leading provider of injectable drugs and infusion technologies, today announced the European Commission (EC) approval of Inflectra™ (infliximab), Europe's first biosimilar monoclonal antibody (mAb) therapy. Inflectra has been approved for the treatment of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis, Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA) and psoriasis.
MedPro Safety Products, Inc., a leading developer of transformational technologies that enable safer medication delivery and blood collection, announced today that it has completed the issuance of a final $5 million tranche of Senior Secured 14% Notes due 2016 in a private placement with institutional investors.
› Verified 7 days ago